Gregory Schmidt, MD
Ophthalmology · Honolulu, HINPI 1740326081
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,822 of the $4,660 with a category attached, or 82.0%. 21 manufacturers reported payments, led by Alcon at 39.3% of the total. 2025 is the largest year on record at $3,370, more than ten times the $20 reported in 2019.
Across 99 payments — averaging $47.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Sight Sciences, Inc.$494
- LEO Pharma Inc.$408
- Bausch & Lomb Americas Inc.$338
- AbbVie$228
- Lilly USA, LLC$195
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,82282%
- Other$83818%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 20 | $1,832 |
| Sight Sciences, Inc. | 10 | $494 |
| LEO Pharma Inc. | 15 | $408 |
| Bausch & Lomb Americas Inc. | 6 | $338 |
| AbbVie | 9 | $228 |
| Lilly USA, LLC | 6 | $195 |
| Glaukos Corporation | 1 | $186 |
| AstraZeneca | 8 | $183 |
| CSL Behring | 6 | $173 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $140 |
| Kedrion Biopharma, Inc. | 1 | $125 |
| Biocryst US Sales Co., LLC | 2 | $58 |
| Cycle Pharmaceuticals Inc | 2 | $55 |
| Tarsus Pharmaceuticals, Inc. | 2 | $44 |
| Sanofi | 2 | $44 |
| Amgen(2 entities) | 2 | $44 |
| Novartis | 2 | $33 |
| Pharming Healthcare, Inc. | 1 | $28 |
| Blueprint Medicines Corporation | 1 | $23 |
| GSK | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Unity$983
- OMNI(R) SURGICAL SYSTEM (US)$421
- Clareon$254
- iDose$186
- ANZUPGO$145
- ENVISTA ENVY IOL$143
- Clareon PanOptix Pro$143
- CATALYS SYSTEM$140
- Coagadex$125
- ORA$101
How this compares
$4,660 in reported general payments places this provider in the 65th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 201 | $251,350 |
| XiidraLifitegrast | 30 | $42,754 |
| Latanoprost | 1,102 | $31,617 |
| CombiganBrimonidine Tartrate/Timolol | 37 | $25,912 |
| MieboPerfluorohexyloctane/Pf | 24 | $22,902 |
| LumiganBimatoprost | 27 | $22,732 |
| Prednisolone Acetate | 282 | $18,894 |
| Brinzolamide | 103 | $18,314 |
| ZyletTobramycin/Lotepred Etab | 27 | $11,147 |
| VyzultaLatanoprostene Bunod | 22 | $11,090 |
| Cyclosporine | 17 | $9,237 |
| Brimonidine Tartrate | 83 | $9,117 |
| TobradexTobramycin/Dexamethasone | 23 | $6,405 |
| Timolol Maleate | 484 | $6,046 |
| MoxifloxacinMoxifloxacin Hcl | 195 | $6,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Lumigan | $228 | $299,994265 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $338 | $76,74676 claims |
| NovartisIlevro | $33 | $4,79313 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $55 | $19215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Honolulu
- Neda NikpoorHonolulu$293K
- Carlton YuenHonolulu$175K
- Alan FaulknerHonolulu$135K
- Michael BennettHonolulu$108K
- Jeffrey PetersonHonolulu$77K
- Rupa WongHonolulu$72K
- Jon PortisHonolulu$20K
- Tyrie JenkinsHonolulu$19K
- John OlkowskiHonolulu$15K
- Claudia HootenHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.